Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab maintenance in frail limited-disease small cell lung cancer after chemoradiotherapy
2021-005920-39Phase 2Active
- Sponsor
- Unicancer
- Start
- May 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in small cell lung cancer (SCLC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival (PFS) by investigator. Started May 2022; status: active.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2021-005920-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005920-39.